Circulating Tumor Cells Are Associated with Survival and Prognosis for Men Receiving Third-line Treatment...
Cabazitaxel, a third-generation taxane, was established as third-line therapy for men with metastatic castration-resistant prostate cancer (mCRPC) by the open-label, phase 4 CARD trial....
